In arm 8 of EPCORE NHL-2 trial, epcoritamab was combined with dose-reduced R-CHOP (R-mini-CHOP) as a frontline therapy for unfit DLBCL patients. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.